Kaposi Sarcoma Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||922000|
|出版日期||內容資訊||英文 111 Pages
|全球卡波西氏肉瘤市場:成長，趨勢，及預測 Kaposi Sarcoma Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 111 Pages||
The growing prevalence of the Kaposi Sarcoma and the rising number of patients undergoing organ transplantation procedures as patients undergoing organ transplantations are more susceptible for Kaposi sarcoma, are the major factor attributing the growth of the Kaposi sarcoma market. According to Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted globally in 2017. Where 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Moreover, the promising number of pipeline studies, growing incidence of HIV-associated Kaposi sarcoma is also a major factor driving Kaposi sarcoma market. However, a shortage in supply of drugs due to a wide demand-supply gap, lack of awareness about this type of cancer, high cost of the treatment and diagnosis of Kaposi sarcoma will impede the growth of the market studied globally.
As per the American Cancer Society, "Kaposi sarcoma (KS) is cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but these tumors can also develop in other parts of the body, such as in the lymph nodes (bean-sized collections of immune cells throughout the body), the lungs, or digestive tract". KS is caused by a virus called human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpes virus (KSHV).
Highly Active Antiretroviral Therapy (HAART) Segment Holds Significant Market Share
North America holds the Largest Market Share in Global Kaposi Sarcoma Market
North America region holds a major market share in the Kaposi treatment market globally. Major factors contributing to this position are the increasing number of product approvals, the presence of many numbers of market players in the market, a high number of R&D initiatives undergoing the treatment and the diagnosis of the Kaposi sarcoma. Additionally, the increasing prevalence of Kaposi sarcoma and HIV is also bolstering the market growth in the region. For instance, According to the American Cancer Society's (ACS) publication, about 1 in 200 transplant recipients in the United States develops Kaposi sarcoma.
Kaposi Sarcoma market has rapidly progressed over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. For instance, in May 2019, The USFDA granted breakthrough therapy designation to Celgene's pomalidomide (Pomalyst) for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.